Druggio

Daiichi Sankyo

Daiichi Sankyo is a pharmaceutical company that focuses on the development and distribution of innovative drugs. They have a strong presence in cardiovascular and metabolic disease treatment, as well as oncology. Founded in 2005 through the merger of two leading Japanese pharmaceutical companies, Daiichi Sankyo has since expanded its global reach and continues to advance treatments for a variety of diseases.

Daiichi Sankyo's Drugs

Made by

Approval date

2021/6/11

Made by

Approval date

2021/1/22

Made by

Approval date

2020/3/25

Treats

Breast cancer Gastric cancer

Made by

Approval date

2019/6/18

Treats

Acute myeloid leukemia

Made by

Approval date

2019/1/8

Treats

Neuropathic pain, Neuralgia

Made by

Approval date

2019/1/8

Treats

High blood pressure, Hypertension

Narusus, Narurapid

Made by

Approval date

2017/3/30

Made by

Approval date

2014/12/26

Treats

Methemoglobinemia

Made by

Approval date

2014/3/24

Treats

Myocardial infarction Angina pectoris

Made by

Approval date

2012/1/18

Treats

Multiple myeloma Rheumatoid arthritis Giant cell tumor of bone Osteoporosis

Made by

Approval date

2011/4/22

Made by

Approval date

2011/1/21

Treats

Alzheimer disease, Dementia due to Alzheimer disease

Made by

Approval date

2010/9/10

Treats

Made by

Approval date

2008/1/25

Made by

Approval date

2006/10/20

Made by

Approval date

2004/1/29

Treats

High blood pressure, Hypertension

Made by

Daiichi Sankyo Daiichi Sankyo

Approval date

2003/1/31

Treats

High blood pressure, Hypertension

Evoxac, Saligren

Made by

Daiichi Sankyo Daiichi Sankyo

Approval date

2001/6/20

Treats

Sjogren syndrome

Made by

Approval date

2000/7/3